IBI-10090 will be Icon’s first product developed using the Verisome® technology to reach the market. IBI-10090 is a biodegradable product for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery.
IBI-10090 is intended to be injected into the anterior chamber of the eye immediately after cataract surgery and safely deliver therapeutic levels of the active ingredient, dexamethasone. It is designed to eliminate the need for anti-inflammatory eye drops in patients undergoing cataract surgery. IBI-10090 should have none of the drawbacks associated with topical eye drops and based on clinical efficacy evidence generated to date will provide the physician and the patient with a clearly superior alternative. In December, 2012 enrollment in a Phase 2/3 pivotal clinical trial was completed. The clinical phase of the trial will be finished in March, 2013.
Data and analysis completed to date indicate IBI-10090 will have a significant efficacy superiority compared to traditional eye drops.
